Therapeutic implications of narrow band ultraviolet B on psoriasis severity and serum levels of acute phase reactants

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Hesham A. Nada ◽  
Mohamed M. Elshabrawy ◽  
Doaa M. Aly ◽  
Mohammad Jafferany ◽  
Mohamed L. Elsaie
Keyword(s):  
Acute Phase ◽  
Narrow Band ◽  
Serum Levels ◽  
Ultraviolet B ◽  
Acute Phase Reactants ◽  
Therapeutic Implications ◽  
Psoriasis Severity

Therapeutic implications and role of serum sphingolipids on psoriasis severity after narrow band ultraviolet B treatment: A cross sectional controlled study

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Hesham A. Nada ◽  
Mohamed M. Elshabrawy ◽  
Nader I. Ismail ◽  
Eman T. Hassan ◽  
Mohammad Jafferany ◽  
...  
Keyword(s):  
Narrow Band ◽  
Ultraviolet B ◽  
Controlled Study ◽  
Cross Sectional ◽  
Therapeutic Implications ◽  
Psoriasis Severity

scholarly journals Effect of COVID-19 on Lipid Profile and its Correlation with Acute Phase Reactants

2021 ◽  
Author(s):  
Jahanzeb Malik ◽  
Uzma Ishaq ◽  
Talha Laique ◽  
Amna Ashraf ◽  
Asmara Malik ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Acute Phase ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Control Group ◽  
Acute Phase Reactants ◽  
And Gender ◽  
Thyroid Profile ◽  
A Prospective Study

Background and Objective Coronavirus disease 2019 (COVID-19) manifests as multiple clinical and pathological organ dysfunctions. It also disrupts metabolic profile due to the release of pro-inflammatory cytokines causing a systemic inflammation reaction. However, the development and correlation of dyslipidemia with acute phase reactants is unknown. This investigation was performed to assess the pathological alterations of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL), triglycerides, and total cholesterol levels in COVID-19 patients. Methods This was a prospective study performed on real-world patients to assess serum levels of LDL-C, HDL, TG, TC on COVID-19 patients (mild: 319; moderate: 391; critical: 357) hospitalized at our center between April 2020 through January 2021. Age- and gender-matched controls who had their lipid profiles in the same period were included as the control group. Results LDL-C, HDL, TG, and TC levels were significantly lower in COVID-19 patients when compared with the control group (P < 0.001, 0.047, 0.045, < 0.001, respectively). All parameters decreased gradually with COVID-19 disease severity (LDL-C: median (IQR), mild: 98 (91,134); moderate: 97 (81,113); critical: 68 (68,83); HDL: mild: 45 (37,50); moderate: 46 (41,50); critical: 40 (37,46); TG: mild: 186 (150,245); moderate: 156 (109,198); critical: 111 (98,154); TC: mild: 224 (212,238); moderate: 212 (203,213); critical: 154 (125,187)). LDL-C, TC, and TG were inversely correlated with acute phase reactants (interleukin-6 (IL-6), Procalcitonin, C-reactive protein (CRP), and D-dimers). Logistic regression demonstrated lipid profile, thyroid profile, and acute phase reactants as predictors of severity of COVID-19 disease. Conclusion Hypolipidemia develops in increasing frequency with severe COVID-19 disease. It inversely correlates with levels of acute-phase reactants, indicating SARS-COV-2 as the causative agent for alteration in lipid and thyroid levels.

scholarly journals Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis

2019 ◽  
Vol 57 (3) ◽  
pp. 274-279 ◽  
Author(s):  
A. S. Avdeeva ◽  
A. M. Satybaldyev ◽  
N. V. Demidova ◽  
N. Yu. Nikishina ◽  
E. V. Gerasimova ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Disease Activity ◽  
Acute Phase ◽  
Active Rheumatoid Arthritis ◽  
Serum Levels ◽  
Biologic Agent ◽  
Acute Phase Reactants ◽  
Reactive Protein ◽  
Real Clinical Practice

Objective:to analyze therapy with rituximab (RTM) in real clinical practice according to the data available in OREL registry of patients with active rheumatoid arthritis (RA).Subjects and methods. The analysis included 349 patients. All the patients received RTM: 340 – the original drug (MabThera®) and 9 – the biosimilar Acellbia®. 263 patients (75.4%) received RTM in combination with disease-modifying anti-rheumatic drugs (DMARDs) and 86 (24.6%) – RTM as monotherapy.Results and discussion. Of the 349 patients included in the analysis, 272 (77.9%) patients received RTM as the first biologic agent (BA) (263 patients were treated with the original drug and 9 – with the biosimilar) and 77 (22.1%) patients had previously used the BA. The majority of patients (n=205 (58.7%)) received three or more; 109 (31.2%) patients – one, and 35 (10%) – two RTM courses of RTM therapy. RTM caused a significant reduction in disease activity just after the first therapy course and in the levels of acute-phase reactants (C-reactive protein (CRP) and ESR); after the fifth therapy course, median CRP concentration decreased by 1.4 times and amounted to 7 [1.2; 17.9] mg/l and that of ESR reduced by 1.8 times and was 10 [5; 20] mm/hr (p<0.05).Conclusion.The analysis of RTM therapy in RA patients in real clinical practice demonstrated that in most cases RTM was given as the first BA, in combination with DMARDs, the main agent of which was methotrexate. The use of RTM was accompanied by a significant reduction in disease activity and in the serum levels of acute-phase reactants and autoantibodies.

Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants

1998 ◽  
Vol 46 (1) ◽  
pp. 14-20 ◽  
Author(s):  
K. Ogoshi ◽  
Masao Miyaji ◽  
Kenji Nakamura ◽  
Yasumasa Kondoh ◽  
Hiroyasu Makuuchi ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Acute Phase ◽  
Serum Levels ◽  
Acute Phase Reactants

Therapeutic implications of C‐reactive protein and uric acid in patients with psoriasis before and after narrow band ultraviolet B therapy

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Mamoun Shalaby ◽  
Ahmad Elshahid ◽  
Ahmed Metwaly ◽  
Ayda Ibrahim ◽  
Mohammad Jafferany ◽  
...  
Keyword(s):  
Uric Acid ◽  
Narrow Band ◽  
Ultraviolet B ◽  
C Reactive Protein ◽  
Therapeutic Implications ◽  
Reactive Protein ◽  
Before And After

Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial

Dermatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Maeve Lynch ◽  
Anna Malara ◽  
Irene Timoney ◽  
Sebastian Vencken ◽  
Tomas Ahern ◽  
...  
Keyword(s):  
Narrow Band ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Depression Scale ◽  
Ultraviolet B ◽  
Controlled Clinical Trial ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Uvb Phototherapy ◽  
Psoriasis Severity

<b><i>Background:</i></b> Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. <b><i>Objective:</i></b> We compared the effects of sitagliptin treatment, a DPP-4 inhibitor, in combination with narrow-band ultraviolet-B (NB-UVB) phototherapy compared to NB-UVB alone on psoriasis severity, quality of life, cardiovascular disease risk factors and immune parameters in people with moderate psoriasis without T2DM. <b><i>Methods:</i></b> In this 39-week, single-centre, randomised controlled trial, people were allocated randomly to receive sitagliptin for 24 weeks with NB-UVB or NB-UVB alone. The primary endpoint was the change in Psoriasis Area and Severity Index (PASI) from baseline to 24 weeks. We estimated that 120 participants would be needed to have 80% power to find a significant difference between the groups. <b><i>Results:</i></b> A total of 118 patients were randomised. The median (IQR) baseline PASI was 8.8 (7.5–11.6). At 24 weeks, the mean difference from baseline in PASI (–1.0 [95% CI –2.0 to 0.0]) was significantly larger in the sitagliptin/NB-UVB arm than in the NB-UVB-alone arm (<i>p</i> = 0.044). There were significant differences in the change in Hospital Anxiety and Depression Scale (–2.5 [95% CI –4.0 to –1.0]; <i>p</i> = 0.002) and EuroQol 5-item questionnaire (0.1 [95% CI 0.0–0.1]; <i>p</i> = 0.036) values from baseline to 24 weeks between the sitagliptin/NB-UVB and the NB-UVB-alone arm. There were no treatment-related serious adverse events. <b><i>Conclusion:</i></b> Sitagliptin therapy combined with NB-UVB phototherapy significantly improved psoriasis severity, albeit modestly, compared to NB-UVB phototherapy alone in patients with moderate psoriasis without T2DM.

scholarly journals C-reactive protein and cytokines in the diagnosis of neonatal sepsis

2006 ◽  
Vol 59 (11-12) ◽  
pp. 545-549 ◽  
Author(s):  
Borisav Jankovic ◽  
Dobrila Veljkovic ◽  
Srdjan Pasic ◽  
Zorica Rakonjac ◽  
Dragana Jevtic ◽  
...  
Keyword(s):  
Acute Phase ◽  
Neonatal Sepsis ◽  
Current Knowledge ◽  
Systemic Infection ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Correct Treatment ◽  
Acute Phase Reactants ◽  
Reactive Protein ◽  
Serum Crp

Introduction. Accurate evaluation and correct treatment of neonates for possible sepsis still represent the most challenging clinical tasks. Early diagnosis of neonatal sepsis is largely based on the measurement of serum concentrations of different mediators of systemic inflammation, as well as, on a group of proteins named acute phase reactants. Among acute phase reactants, C-reactive protein (CRP) has been the most extensively used and investigated so far. Synthesis and biological role of CRP. This article reviews current knowledge on the synthesis, structure and biologic roles of CRP. Also, we present our original results in regard to the kinetics of serum CRP concentration during the first 24 hours of systemic infection, as well as different patterns of CRP dynamics associated with the initial choice of antibiotics, complications and the final outcome of systemic infection. Interleukins and procalcitonin in diagnosis of sepsis. Because CRP is specific, but somewhat late marker of neonatal sepsis, possible diagnostic use of other indicators of inflammation, i.e. interleukins 6 and 8, and procalcitonin during neonatal sepsis is also considered. The theoretical advantage of these early indicators is discussed in comparative analysis of the time of their activation after initial infectious stimuli. Conclusion. In conclusion, we point to the diagnostic accuracy of serial measurements of serum CRP levels. As an alternative, simultaneous measurement of CRP and serum levels using a faster marker, such as procalcitonin, is recommended.

Sign in / Sign up

Export Citation Format

Share Document